{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:20:58Z","timestamp":1793064058278,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41371-019-0267-y","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T13:12:42Z","timestamp":1571663562000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Malignant hypertension: does this still exist?"],"prefix":"10.1038","volume":"34","author":[{"given":"Magdalena","family":"Domek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Gumprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0594-8576","authenticated-orcid":false,"given":"Alena","family":"Shantsila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"267_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00000441-197412000-00004","volume":"268","author":"NM Keith","year":"1974","unstructured":"Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1974;268:336\u201345.","journal-title":"Am J Med Sci"},{"key":"267_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/ajh\/hpx008","volume":"30","author":"A Shantsila","year":"2017","unstructured":"Shantsila A, Lip GYH. Malignant hypertension revisited\u2014does this still exist? Am J Hypertens. 2017;30:543\u20139.","journal-title":"Am J Hypertens"},{"key":"267_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/jhh.2015.112","volume":"30","author":"A Cremer","year":"2016","unstructured":"Cremer A, Amraoui F, Lip GYH, Morales E, Rubin S, Segura J, et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens. 2016;30:463\u20136.","journal-title":"J Hum Hypertens"},{"key":"267_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/ajh.2009.153","volume":"22","author":"DA Lane","year":"2009","unstructured":"Lane DA, Lip GYH, Beevers DG. Improving survival of malignant hypertension patients over 40 years. Am J Hypertens. 2009;22:1199\u2013204.","journal-title":"Am J Hypertens"},{"key":"267_CR5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1097\/00004872-199411000-00013","volume":"12","author":"GY Lip","year":"1994","unstructured":"Lip GY, Beevers M, Beevers G. The failure of malignant hypertension to decline: a survey of 24 years\u2019 experience in a multiracial population in England. J Hypertens. 1994;12:1297\u2013305.","journal-title":"J Hypertens"},{"key":"267_CR6","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1097\/01.hjh.0000249710.21146.38","volume":"24","author":"B-JH van den Born","year":"2006","unstructured":"van den Born B-JH, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006;24:2299\u2013304.","journal-title":"J Hypertens"},{"key":"267_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/sj.jhh.1000963","volume":"14","author":"S Kadiri","year":"2000","unstructured":"Kadiri S, Olutade BO, Osobamiro O. Factors influencing the development of malignant hypertension in Nigeria. J Hum Hypertens. 2000;14:171\u20134.","journal-title":"J Hum Hypertens"},{"key":"267_CR8","first-page":"339","volume":"5","author":"S Kadiri","year":"1991","unstructured":"Kadiri S, Olutade BO. The clinical presentation of malignant hypertension in Nigerians. J Hum Hypertens. 1991;5:339\u201343.","journal-title":"J Hum Hypertens"},{"key":"267_CR9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S0895-7061(99)00283-6","volume":"13","author":"GYH Lip","year":"2000","unstructured":"Lip GYH, Beevers M, Beevers DG. Do patients with de novo hypertension differ from patients with previously known hypertension when Malignant phase hypertension occurs? Am J Hypertens. 2000;13:934\u20139.","journal-title":"Am J Hypertens"},{"key":"267_CR10","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1136\/bmj.1.5134.1361","volume":"1","author":"AW Leishman","year":"1959","unstructured":"Leishman AW. Hypertension: treated and untreated; a study of 400 cases. Br Med J. 1959;1:1361\u20138.","journal-title":"Br Med J"},{"key":"267_CR11","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1097\/HJH.0000000000001446","volume":"35","author":"A Shantsila","year":"2017","unstructured":"Shantsila A, Shantsila E, Beevers DG, Lip GYH. Predictors of 5-year outcomes in malignant phase hypertension: The West Birmingham Malignant Hypertension Registry. J Hypertens. 2017;35:2310\u20134.","journal-title":"J Hypertens"},{"key":"267_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/jch.12243","volume":"16","author":"F Amraoui","year":"2014","unstructured":"Amraoui F, Van Der Hoeven NV, Van Valkengoed IGM, Vogt L, Van Den Born B-JH. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens. 2014;16:122\u20136.","journal-title":"J Clin Hypertens"},{"key":"267_CR13","first-page":"S405","volume":"3","author":"CG Isles","year":"1985","unstructured":"Isles CG, Lim KG, Boulton-Jones M, Cameron H, Lever AF, Murray G, et al. Factors influencing mortality in malignant hypertension. J Hypertens Suppl. 1985;3:S405\u20137.","journal-title":"J Hypertens Suppl"},{"key":"267_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-2369-13-71","volume":"13","author":"F Amraoui","year":"2012","unstructured":"Amraoui F, Bos S, Vogt L, van den Born B-J. Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study. BMC Nephrol. 2012;13:71.","journal-title":"BMC Nephrol"},{"key":"267_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1055\/s-0034-1396333","volume":"232","author":"K Steinegger","year":"2015","unstructured":"Steinegger K, Bergin C, Guex-Crosier Y. Malignant hypertension: clinical manifestations of 7 cases. Klin Monbl Augenheilkd. 2015;232:590\u20132.","journal-title":"Klin Monbl Augenheilkd"},{"key":"267_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/CRD.0b013e3181c307b7","volume":"18","author":"MA Rodriguez","year":"2010","unstructured":"Rodriguez MA, Kumar SK, De Caro M. Hypertensive crisis. Cardiol Rev. 2010;18:102\u20137.","journal-title":"Cardiol Rev"},{"key":"267_CR17","first-page":"669","volume":"26","author":"Y-H Chen","year":"2003","unstructured":"Chen Y-H, Kuo H-K, Kao M-L. Malignant hypertensive retinopathy-clinical and fundus manifestations in patients with new onset or acute exacerbation of chronic hypertension. Chang Gung Med J. 2003;26:669\u201377.","journal-title":"Chang Gung Med J"},{"key":"267_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:17.","journal-title":"Eye Vis"},{"key":"267_CR19","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/ped.12525","volume":"57","author":"G Cortina","year":"2015","unstructured":"Cortina G, Hofer J, Giner T, Jungraithmayr T. Severe visual loss caused by unrecognized malignant hypertension in a 15-year-old girl. Pediatr Int. 2015;57:e42\u2013e44.","journal-title":"Pediatr Int"},{"key":"267_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/10641963.2010.503304","volume":"33","author":"Z Balogh","year":"2011","unstructured":"Balogh Z, Berta A, Pfliegler G, Nagy V. Bilateral central retinal vein occlusion caused by malignant hypertension in a young patient. Clin Exp Hypertens. 2011;33:53\u201355.","journal-title":"Clin Exp Hypertens"},{"key":"267_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1161\/HYPERTENSIONAHA.110.166314","volume":"57","author":"A Shantsila","year":"2011","unstructured":"Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GYH. Persistent macrovascular and microvascular dysfunction in patients with malignant hypertension. Hypertension. 2011;57:490\u20136.","journal-title":"Hypertension"},{"key":"267_CR22","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1093\/ndt\/gfq143","volume":"25","author":"R Gonzalez","year":"2010","unstructured":"Gonzalez R, Morales E, Segura J, Ruilope LM, Praga M. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant. 2010;25:3266\u201372.","journal-title":"Nephrol Dial Transplant"},{"key":"267_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5414\/CNP73147","volume":"73","author":"L Shavit","year":"2010","unstructured":"Shavit L, Reinus C, Slotki I. Severe renal failure and microangiopathic hemolysis induced by malignant hypertension-case series and review of literature. Clin Nephrol. 2010;73:147\u201352.","journal-title":"Clin Nephrol"},{"key":"267_CR24","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1055\/s-0029-1241930","volume":"134","author":"N Gassanov","year":"2009","unstructured":"Gassanov N, Pollok M, Er F. Akutes Nierenversagen bei maligner Hypertonie [Acute renal failure associated with malignant hypertension]. Dtsch Medizinische Wochenschr. 2009;134:2224\u20137.","journal-title":"Dtsch Medizinische Wochenschr"},{"key":"267_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","volume":"45","author":"BJH van den Born","year":"2005","unstructured":"van den Born BJH, Honnebier UPF, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005;45:246\u201351.","journal-title":"Hypertension"},{"key":"267_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijcard.2011.11.077","volume":"167","author":"A Shantsila","year":"2013","unstructured":"Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GYH. A comprehensive assessment of cardiac structure and function in patients with treated malignant phase hypertension: The West Birmingham Malignant Hypertension project. Int J Cardiol. 2013;167:67\u201372.","journal-title":"Int J Cardiol"},{"key":"267_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/HYPERTENSIONAHA.116.07901","volume":"68","author":"GYH Lip","year":"2016","unstructured":"Lip GYH. Atrial fibrillation in patients with hypertension. Hypertension. 2016;68:544\u20135.","journal-title":"Hypertension"},{"key":"267_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0140-6736(00)02539-3","volume":"356","author":"CJ Vaughan","year":"2000","unstructured":"Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411\u20137.","journal-title":"Lancet"},{"key":"267_CR29","first-page":"1956","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC\/ESHGuidelines for themanagement of arterial hypertension. J Hypertens 2018;36:1956\u20132041.","journal-title":"J Hypertens"},{"key":"267_CR30","first-page":"37","volume":"5","author":"B-JH van den Born","year":"2019","unstructured":"van den Born B-JH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Hear J. 2019;5:37\u201346.","journal-title":"Eur Hear J"},{"key":"267_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11906-014-0515-z","volume":"17","author":"DP Papadopoulos","year":"2015","unstructured":"Papadopoulos DP, Sanidas EA, Viniou NA, Gennimata V, Chantziara V, Barbetseas I, et al. Cardiovascular hypertensive emergencies. Curr Hypertens Rep. 2015;17:5.","journal-title":"Curr Hypertens Rep"},{"key":"267_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jama.1991.03470060091033","volume":"266","author":"RW Gifford","year":"1991","unstructured":"Gifford RW. Management of hypertensive crises. J Am Med Assoc. 1991;266:829\u201335.","journal-title":"J Am Med Assoc"},{"key":"267_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3949\/ccjm.61.1.59","volume":"61","author":"DG Vidt","year":"1994","unstructured":"Vidt DG, Bakst A, Pearce CJ, Wallin JD. Labetalol and other agents that block both alpha- and beta-adrenergic receptors. Cleve Clin J Med. 1994;61:59\u201369.","journal-title":"Cleve Clin J Med"},{"key":"267_CR34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/0888-6296(89)90120-8","volume":"3","author":"P Turlapaty","year":"1989","unstructured":"Turlapaty P, Vary R, Kaplan JA. Nicardipine, a new intravenous calcium antagonist: a review of its pharmacology, pharmacokinetics, and perioperative applications. J Cardiothorac Anesth. 1989;3:344\u201355.","journal-title":"J Cardiothorac Anesth"},{"key":"267_CR35","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/HJH.0b013e3283430b12","volume":"29","author":"P Gosse","year":"2011","unstructured":"Gosse P, Coulon P, Papaioannou G, Litalien J, Lemetayer P. Impact of malignant arterial hypertension on the heart. J Hypertens. 2011;29:798\u2013802.","journal-title":"J Hypertens"},{"key":"267_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","volume":"37","author":"S Rubin","year":"2019","unstructured":"Rubin S, Cremer A, Boulestreau R, Rigothier C, Kuntz S, Gosse P. Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. J Hypertens. 2019;37:316\u201324.","journal-title":"J Hypertens"},{"key":"267_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/cc2351","volume":"7","author":"J Varon","year":"2003","unstructured":"Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care. 2003;7:374\u201384.","journal-title":"Crit Care"},{"key":"267_CR38","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/HJH.0b013e3283526e47","volume":"30","author":"A Shantsila","year":"2012","unstructured":"Shantsila A, Lane DA, Beevers DG, Lip GYH. Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension. J Hypertens. 2012;30:974\u20139.","journal-title":"J Hypertens"},{"key":"267_CR39","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation CHEST guideline and expert panel report. Chest 2018;154:1121\u2013201.","journal-title":"Chest"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-019-0267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-019-0267-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-019-0267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T15:15:43Z","timestamp":1654787743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-019-0267-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1038\/s41371-019-0267-y","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"5 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}